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The ability of allopurinol to protect against
reperfusion injury in the heart has usually been
attributed to its xanthine oxidase (XO)-
inhibiting properties. Human myocardium how-
ever, has exhibited low levels of XO activity. To
investigate the effects of allopurinol in an
XO-free model and determine whether pretreat-
ment is necessary, 12 domestic pigs (15 kg to
20 kg) underwent occlusion of the left circum-
flex for 8 minutes followed by reperfusion for 4
hours. One group received allopurinol infusion
(5 mg/kg IV) at occlusion over 45 minutes and a
control group (n = 6) received a saline infusion
(same volume). Left ventricular and aortic
pressure, electrocardiograms, and regional
wall motion (sonomicrometry) were monitored
throughout the process. Regional blood flow
(microspheres) were obtained before, during,
and 5, 10, and 30 minutes after ischemia.
Occlusion decreased transmural flow at the
midpapillary level by 75% (0.28 versus 1.10
mUminute/g). The allopurinol-treated group
exhibited a mild, generalized hyperemia at 5
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minutes (ischemic zone: 1.44 versus 1.10 mU
min/g, which returned to control levels at 10
and 30 minutes. In contrast, the control group
was associated with only 80% restoration of
resting blood flow at 5 minutes (0.84 versus
1.10 mUmin/g), which stabilized at 63% of
control levels at 10 and 30 minutes. When
evaluated for the propensity of arrhythmias
using an arbitrary arrhythmia score, the al-
lopurinol group demonstrated no myocardial
ectopy when compared with the focal ectopy
routinely encountered in the control group at
all time intervals. Since pigs have no detectable
levels of XO activity, allopurinol must exert its
protectant effect during myocardial reperfu-
sion by an alternative mechanism. Because
protection was evident without pretreatment,
beneficial effects may not necessarily be the
result of allopurinol degradation products;
therefore, pretreatment with allopurinol may
not be necessary. These results are clinically
important when considering the use of allopuri-
nol in an emergent coronary angioplasty or
coronary artery bypass grafting. (J Nati Med
Assoc. 1995;87:480-484.)
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Restoration of myocardial function following global
ischemia associated with cardioplegic arrest and coro-
nary artery bypass surgery is a major concern to
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cardiothoracic surgeons. Poorly contracting myocar-
dium caused by reperfusion of previously ischemic
tissue produces an injury, or "stun," that is believed to
be a factor in the induction of fatal arrhythmias and
heart failure, which ultimately may lead to death.'
In an attempt to reduce this injury, the effectiveness
of several pharmacological interventions have been
investigated, including glucose, insulin, potassium,
hyaluronidase, (3-blockers, and calcium channel antago-
nists.1.2 More recently, therapies directed at reducing
the impact of reactive oxygen species, oxygen-derived
free radicals (ODFRs), have generated much scrutiny.
One such therapeutic agent is allopurinol.
Beneficial effects observed with allopurinol in the
setting of ischemia and reperfusion injury in the
myocardium have been attributed to its ability to reduce
the formation of ODFRs by inhibiting the enzyme
XO.3-6 However, these data largely have been generated
from animal models (dogs and rats), which have
demonstrated substantial XO enzyme activity. How-
ever, allopurinol also has been reported as therapeutic in
animal systems with no detectable XO activity.7-8
Human myocardial biopsies have demonstrated very
little XO enzymatic activity.6 Therefore, the exact role
of allopurinol in limiting the effects of ODFRs and
myocardial reperfusion injury remains uncertain.
Clearly, the data suggest that allopurinol reduces
myocardial reperfusion injury by mechanisms other
than inhibition of XO-generated ODFRs. At least one
suggestion is that pretreatment with allopurinol leads to
accumulation of the degradation product oxypurinol,
which has ODFR-scavenging effects.8 To further
evaluate the efficacy of allopurinol and/or pretreatment,
a "stun" paradigm was investigated in a pig model
which has been shown to exhibit no XO activity.6,8
METHODS
Twelve domestic pigs (15 kg to 20 kg) were
anesthetized using sodium pentobarbital (10 mg/kg
bolus; 7 mg/kg/hour infusion), intubated, and venti-
lated with positive pressure and room air. A median
sternotomy was performed. Left atrial, left ventricu-
lar, arterial, and venous cannulas were placed. Pairs
of sonomicrometry crystals were placed in the
distribution of the circumflex (ischemic, posterior)
and the anterior (control) descending coronary arter-
ies. Segment length was measured according to
electrocardiogram (ECG)-gated times for end-systole
and end-diastole, and relative shortening was calcu-
lated as an index of myocardial function in each
region.
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Figure 1. Mean transmural blood flow in the
posterior papillary region. Note that both
groups showed significant decreases during
occlusion, as expected, while only the al-
lopurinol-treated group demonstrated remark-
able hyperemia and restoration of baseline
flows during reperfusion.
The left circumflex artery was gently dissected free
of interstitial connections, and a snare was placed.
The animal was then allowed to stabilize. Following
stabilization, local occlusion of the left circumflex
artery was accomplished and maintained for 8
minutes. After the 8-minute ischemic period, the left
circumflex artery was reopened and allowed to
reperfuse the ischemic myocardium for a period of 4
hours. One group (n = 6) received an intravenous
allopurinol infusion (5 mg/kg) beginning at the time
of occlusion and continuing for 45 minutes (37th
minute of reperfusion). A second group (n = 6)
received a comparable saline infusion (vehicle con-
trol) over the same period. Left ventricular and aortic
pressure, ECG (lead II), and regional wall motion
(sonomicrometry) were monitored and recorded
throughout the experiment.
Regional myocardial blood flow, using the refer-
ence withdrawal method as established in our
laboratory,9 was determined using microspheres
before, during, and 5, 10, and 30 minutes after
ischemia was produced. At the end of the experiment,
the animal was killed by lethal overdose, and the
heart was removed. After formalin fixation for 5
days, the myocardium was sectioned, and tissue was
analyzed for radioactivity, which was then converted
to flow by computer analysis and normalized for
sample weight. This produced final blood flow
measurements expressed in mL/minutes/g.
An arrhythmia score was developed: 0= no ectopy,
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Figure 2. Mean transmural flow in the anterior
papillary region. Note that the allopurinol-
treated group displayed a significant hypere-
mia during the occlusive episode in the adja-
cent region, which was sustained early during
reperfusion. Blood flow patterns later during
reperfusion were not significantly different.
no tachycardia; 1 = isolated ventricular ectopy or
periods of sinus tachycardia; 2 =interrupted runs of
ventricular tachycardia (V-tach); 3 = sustained V-
tach (continuously for 10 seconds); and 4 = ventricu-
lar fibrillation. Arrhythmogenicity during ischemic
and reperfusion periods was evaluated.
All experiments were conducted under protocols
approved by the institutional animal care and use
committee, and methods of anesthesia and euthanasia
were consistent with National Institutes of Health
guidelines. All data were analyzed using multivariate
analysis of variance for repeated measures, using
Dunnett's multiple range test as appropriate. Signifi-
cance was determined when P<.05.
RESULTS
Blood Flow
Occlusion of the left circumflex artery decreased
transmural blood flow 75% in both groups (0.28
versus 1.10 mL/minutes/g; P<.01). During reperfu-
sion, the allopurinol-treated group demonstrated a
mild, generalized hyperemia at 5 minutes that was
significantly greater than baseline (1.44 versus 1.10
mL/minutes/g; P<.01). In addition, the allopurinol-
treated group sustained baseline blood flow levels at
10 and 30 minutes of reperfusion. In contrast, the
saline group exhibited a defective reperfusion. At 5
minutes of reperfusion, flow remained 20% below
baseline (0.84 versus 1.10 mL/minutes/g; P<.05). At
10 and 30 minutes, the untreated group showed a
further decrease in adequate reperfusion. Blood flow
stabilized at only 63% of baseline levels. In sum-
mary, allopurinol was associated with preservation of
physiologic reactive hyperemia and preservation of
normal flow distribution during reperfusion. Both
were defective in comparable controls (Figure 1). In
addition, allopurinol treatment was associated with
improved perfusion to the nonischemia anterior
segments during occlusion (Figure 2). The improved
hyperemia in the nonischemic segments may have
important ramifications in supporting compensatory
recruitable wall motion adjacent to the ischemic
tissue.
Arrhythmogenicity
Using the defined arrhythmia score, the propensity of
the reperfused myocardium to develop arrhythmias was
evaluated. The allopurinol-treated group demonstrated
no myocardial ectopy, while dramatic, focal, and
myocardial ectopy was routinely encountered in the
untreated group at all time intervals (P<.05).
Wall Motion
In general, allopurinol treatment did not have a
significant effect on wall motion in the nonischemic
myocardium, except during the immediate occlusion,
when there was a remarkable retention of shortening
compared with saline-treated groups (Figure 3).
Thus, in the nonoccluded region, the effect of
allopurinol is manifest during ischemia in the
adjacent region, but little effect was observed during
reperfusion. In contrast, wall motion in the occluded
region was not preserved in the allopurinol-treated
group; however, with reperfusion, allopurinol treat-
ment was associated with a much stronger, sustained
recovery of myocardial shortening (Figure 4). To-
gether, both wall motion data and perfusion data
suggest a bimodal efficacy for allopurinol treatment,
with a beneficial effect during occlusion manifest in
the nonischemic tissue beds, and a beneficial effect
during reperfusion in the previously ischemic tissue
but not the nonischemic tissue.
DISCUSSION
Allopurinol has been suggested to improve myocar-
dial reperfusion injury by reducing the number of
ODFRs secondary to competitive inhibition of XO.3-5
Xanthine oxidase uses molecular oxygen as an electron
acceptor.5 These ODFRs are able to produce myocar-
dial alterations characteristic of ischemic-reperfusion
injury, including disruption of plasma membranes and
lysosomes, damage to mitochondria and sarcoplasmic
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Figure 3. Change from baseline in shortening
fraction in the anterior region. Note that while
shortening was generally comparable
throughout the experiment, during the occlu-
sion of the adjacent region, allopurinol was
associated with wall motion preservation that
was 10% better than the control group. While
this may not be a factor in otherwise-normal
myocardium, as in these experiments, this
difference may be important in diseased myo-
cardium.
reticulum, increases in vascular permeability, and the
initiation of ventricular arrhythmias.1
Despite this observation, the involvement of XO and
allopurinol in myocardial preservation during ischemic-
reperfusion remains unclear. The activity of XO has
varied from one study to another, as well as from
species to species, which is also confusing. No XO
activity has been reported in pig myocardium. Simi-
larly, rabbit and human myocardial biopsies have
exhibited little XO enzymatic activity. However,
moderate to high levels of XO have been detected in
both dogs and guinea pigs.6
Using the pig model, our results demonstrate that
allopurinol does have beneficial and protective
effects during myocardial reperfusion after an acute,
non-necrosing ischemic period. Since no XO enzyme
activity was present in this model, the beneficial
effects observed with allopurinol administration
must be attributed to a mechanism other than
inhibition of XO.
The allopurinol-treated group exhibited superior resto-
ration of blood flow during the reperfusion period when
compared to the untreated group. Myocardial ectopy also
was reduced dramatically in the allopurinol-treated group.
Our data are consistent with other investigations which
have shown allopurinol to exert beneficial effects in
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Figure 4. Change from baseline in shortening
fraction in the posterior region. Note that, in
contrast to the anterior region, no effect of
allopurinol treatment could be demonstrated
during ischemic occlusion. However, on
reperfusion, a sustained recovery in shorten-
ing was observed. Allopurinol was associated
with a full recovery of wall motion in the
previously ischemic tissue within 30 minutes,
while saline control had recovered only 75% of
baseline function as late as 4 hours after
reperfusion had been established.
rabbit hearts, the rabbit being an animal that also is
reported to have little XO activity.'
Many factors are believed to contribute to the
generation of reperfusion injury. In general, these factors
may be categorized into three groups: injuries related to
ultrastructural damage and the inability to regulate
calcium flux, injuries related to the production of ODFRs,
and injuries that result from acute inflammatory re-
sponses in the previously ischemic region.7 Das et al8
used biochemical analysis to demonstrate that both
oxypurinol and allopurinol may salvage myocardial
function during ischemia and reperfusion by scavenging
ODFRs rather than by inhibiting XO. Together, these data
suggest that xanthine oxidase probably is not the principal
source of ODFRs and that allopurinol has a direct
scavenging effect on ODFRs.
Certain protective actions of allopurinol, such as the
preservation of cellular adenosine triphosphate (ATP)
levels and of mitochondrial ATP-generating capacity,
have been shown to be exerted predominantly during the
ischemic phase of injury. Other beneficial actions, such as
preventing a decrease in left ventricular pressure,
decreasing sodium and calcium accumulation, and
preserving sarcolemmal and sarcoplasmic reticular
ATPases, are greater during the reperfusion phase of
injury. This would imply that the molecular processes
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determining cellular injury are mechanistically different
during these two phases.' Beneficial effects observed
with allopurinol may be exerted at different phases of
injury.
In addition, our data clearly show that the protective
effects do not depend on pretreatment, suggesting that
improved recovery may not require allopurinol degra-
dation to oxypurinol. Therefore, pretreatment with
allopurinol may not be necessary, as was the case in our
study. This is an important clinical consideration when
treating a patient suffering from an acute ischemic event.
Xanthine oxidase catalyzes the irreversible oxidation
of hypoxanthine to xanthine and to uric acid, possibly
accelerating the ischemic breakdown of purine nucleo-
sides and bases that are needed for the resynthesis of ATP
during reperfusion.6,"0 DeWall et al2l' have suggested
that XO inhibition might be protective by facilitating
purine salvage, thereby enabling ischemic tissues to
maintain their ATP scores. However, others have
suggested that this mechanism is unlikely because the
washout of nucleotide degradation products is too rapid. 12
SUMMARY
Despite controversy, there is a growing body of
evidence to support the theory that allopurinol exhibits
its beneficial effects by more than one mechanism and
pathway. The results of this study demonstrate clearly
that allopurinol exerts a significant protective effect
during myocardial reperfusion injury by mechanisms or
pathways other than the inhibition of XO, and pretreat-
ment with allopurinol is not required. Future studies to
specifically identify these mechanisms and pathways,
as well as dosage strategies, are needed.
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